ACADライブシグナル | Getagraph.comで利益を最大化

売る 107770 min ago

@ $25.78

発行日: 15 2月 2024 @ 05:32

リターン: -32.39%

前回のシグナル: 2月 15 - 03:10

前回のシグナル: 買う

リターン: 0.72 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:42):

Stats
本日の出来高	384 905
平均出来高	1.80M
時価総額	2.87B
EPS	$0 ( 2024-02-27 )
次の収益日	( $0.170 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-47.11
ATR14	$0.0190 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-04	Thompson Elizabeth H.z.	Buy	0
2024-04-05	Davis Stephen	Buy	34 666	Common Stock
2024-04-08	Davis Stephen	Sell	8 858	Common Stock
2024-04-08	Davis Stephen	Sell	17 716	Common Stock
2024-04-05	Davis Stephen	Sell	34 666	Restricted Stock Units

INSIDER POWER
31.79
Last 98 transactions
Buy: 1 174 699 \| Sell: 709 800

ボリューム相関

長: -0.02 (neutral)

短: 1.00 (very strong)

Signal:(56.332) Expect same movement, but be aware

ACADIA Pharmaceuticals 相関

10 最も正の相関
BIOL	0.951
SONN	0.938
BGXX	0.936
AKTS	0.935
WB	0.935
HCM	0.934
ALLR	0.933
COKE	0.931
PROG	0.931
PHUN	0.93

10 最も負の相関
TUEM	-0.954
LCA	-0.936
USCB	-0.933
MCAA	-0.929
MSDA	-0.928
FXCO	-0.926
PRSR	-0.926
MSDAU	-0.925
ACBA	-0.923
BRIVU	-0.923

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

ACADIA Pharmaceuticals 相関 - 通貨/商品

-0.12
( neutral )

-0.35
( neutral )

0.00
( neutral )

0.59
( weak )

0.64
( weak )

0.61
( weak )

ACADIA Pharmaceuticals 財務諸表

Annual	2023
収益:	$726.44M
総利益:	$680.71M (93.70 %)
EPS:	$-0.370

FY	2023
収益:	$726.44M
総利益:	$680.71M (93.70 %)
EPS:	$-0.370

FY	2022
収益:	$517.24M
総利益:	$507.07M (98.03 %)
EPS:	$-1.340

FY	2021
収益:	$484.15M
総利益:	$465.00M (96.05 %)
EPS:	$-1.067

Financial Reports:

No articles found.

ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.